| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.02 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.02 |
| mRNA | GW-2580 | GDSC1000 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.08 | 0.02 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.079 | 0.02 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.02 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.02 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.02 |